The radioligand binding approach in the study of lymphocytic adrenoceptors and the constitutional basis of atopy.
D000249:Adenosine Monophosphate / Q000378:metabolism; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000402:Airway Obstruction / Q000276:immunology; D000818:Animals; D001001:Anura; D001249:Asthma / Q000188:drug therapy / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D001665:Binding Sites; D002395:Catecholamines / Q000627:therapeutic use; D002462:Cell Membrane / Q000276:immunology; D003876:Dermatitis, Atopic / Q000188:drug therapy; D004082:Dihydroalprenolol / Q000627:therapeutic use; D004088:Dihydroergotoxine / Q000627:therapeutic use; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D011869:Radioligand Assay; D013601:T-Lymphocytes / Q000276:immunology
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D004088:Dihydroergotoxine; D000249:Adenosine Monophosphate; D004082:Dihydroalprenolol